Journal for ImmunoTherapy of Cancer (Nov 2023)
837 Combination treatment with ATOR-4066, a Neo-X-Prime™ bispecific antibody targeting CD40 and CEACAM5, and anti-PD-1 reverses T cell exhaustion in vitro
Abstract
No abstracts available.
Journal for ImmunoTherapy of Cancer (Nov 2023)